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Abstract
Background Cancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical func-
tion. It has been suggested that the optimal treatment for cachexia should be a multimodal intervention. The primary aim of
this study was to examine the feasibility and safety of a multimodal intervention (n-3 polyunsaturated fatty acid nutritional
supplements, exercise, and anti-inﬂammatory medication: celecoxib) for cancer cachexia in patients with incurable lung or
pancreatic cancer, undergoing chemotherapy.
Methods Patients receiving two cycles of standard chemotherapy were randomized to either the multimodal cachexia inter-
vention or standard care. Primary outcome measures were feasibility assessed by recruitment, attrition, and compliance with
intervention (>50% of components in>50% of patients). Key secondary outcomes were change in weight, muscle mass, phys-
ical activity, safety, and survival.
Results Three hundred and ninety-nine were screened resulting in 46 patients recruited (11.5%). Twenty ﬁve patients were
randomized to the treatment and 21 as controls. Forty-one completed the study (attrition rate 11%). Compliance to the indi-
vidual components of the intervention was 76% for celecoxib, 60% for exercise, and 48% for nutritional supplements. As ex-
pected from the sample size, there was no statistically signiﬁcant effect on physical activity or muscle mass. There were no
intervention-related Serious Adverse Events and survival was similar between the groups.
Conclusions A multimodal cachexia intervention is feasible and safe in patients with incurable lung or pancreatic cancer;
however, compliance to nutritional supplements was suboptimal. A phase III study is now underway to assess fully the effect
of the intervention.
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Introduction
Cancer cachexia is a multifactorial syndrome characterized
by weight loss, muscle wasting, and symptoms such as
fatigue and anorexia.1 It is a severe, unrelieved cause of
suffering in patients and is associated with increased mor-
tality,2 increased chemotherapy toxicity, and reduced quality
of life.1 It is estimated that more than 80% of patients with
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advanced cancer disease will experience weight loss or
cachexia.3
The pathophysiology of cancer cachexia is a combination
of reduced food intake and altered metabolism resulting
from complex interactions between inﬂammation, hyperme-
tabolism, neuro-hormonal changes, increased catabolism,
and reduced muscle/fat anabolism.4 Despite increased un-
derstanding of the mechanisms of cachexia, there is still no
standard of care, no licensed drug treatment, and no
evidence-based guidelines on the management of cachexia.
Thus, clinicians and patients often regard cachexia as an inev-
itable consequence of cancer. This lack of treatment progress
is paradoxical given the importance of this condition in limit-
ing oncology treatment success and contributing to excess
morbidity andmortality. New approaches are needed to break
the deadlock: approaches that address the complexity of the
syndrome and challenge the accepted therapeutic nihilism.
Systematic reviews have shown that uni-modal interven-
tions employing (i) nutritional counselling and oral nutritional
supplements (ONS),5 (ii) physical exercise training,6 (iii) non-
steroidal anti-inﬂammatory drugs7 (NSAIDs), or (iv) omega
(n-3) polyunsaturated fatty acid supplementation,8,9 can im-
prove nutritional and functional outcomes. Unfortunately,
within each systematic review, there was considerable het-
erogeneity between studies, and few studies had an ade-
quate sample size. As such, these individual treatment
effects have not been sufﬁciently strong to change clinical
practice. To treat cachexia optimally, it has been argued that
a multimodal intervention is necessary10 to enable the multi-
factorial pathophysiology to be targeted and achieve at least
additional, if not synergistic effects.
It has been argued that the optimal time to initiate any ca-
chexia therapy is early in the disease trajectory, indeed be-
fore cachexia has become established: preventing cachexia
rather than treating it. In practical terms, this means that ca-
chexia interventions should be given alongside tumour-
directed treatment. This approach has the advantage that
chemotherapy-induced muscle loss may also be reduced.11
Undertaking cachexia treatment early in the disease trajec-
tory during chemotherapy may provide a therapeutic window
where the chances to establish a clinically meaningful beneﬁt
are maximal.
Taken together, the aforementioned observations form a
persuasive argument that a multimodal cachexia intervention
[nutritional therapy with eicosapentaenoic acid (EPA), physi-
cal exercise and anti-inﬂammatory treatment (celecoxib)]
should be examined in a robust clinical trial. This intervention
should be delivered in tumour groups where cachexia is prev-
alent (lung and pancreatic cancer) and early in the disease
trajectory to achieve optimal clinical beneﬁt.
However, a multimodal intervention such as this is chal-
lenging both in terms of compliance with the intervention
and in the timing of delivery. Therefore, the aim of this
randomized phase II study was to assess the feasibility
and potential efﬁcacy of a multimodal intervention to atten-
uate cachexia in patients with incurable lung or pancreatic
cancer.
Methods
Study design and participants
A phase II, randomised, open-label feasibility trial was con-
ducted—ClinicalTrials.gov: NCT01419145. Eligible patients
met the following criteria: age 18–80 years; stage III/IV non-
small cell lung cancer or inoperable pancreatic cancer; due
to commence chemotherapy; Karnofsky performance status
>70; no contraindication to the study interventions (primar-
ily the anti-inﬂammatory medication); body mass index
<30 kg/m2; and <20% weight loss in the previous 6 months.
Patients who had received any systemic anti-cancer therapy
in the preceding 4 weeks, or who were taking regular oral ste-
roid medication, were not eligible. Patients who were partic-
ipating in other interventional clinical trials or who within
30 days prior to inclusion were taking other agents for the
prevention or treatment of cachexia (such as megestrol ace-
tate, progestational agents, growth hormone, dronabinol,
marijuana, or other anabolic agent) were not eligible. Pa-
tients with renal impairment deﬁned as creatinine clearance
<30 mL/min were not eligible. Patients with potential
contra-indications to celecoxib [New York Heart Association
Functional class III or IV heart failure, uncontrolled hyperten-
sion (diastolic blood pressure > 95 mmHg at screening), his-
tory of previous myocardial infarction, unstable angina,
coronary revascularization, uncontrolled arrhythmia, cerebro-
vascular accident, previous gastrointestinal inﬂammatory dis-
ease and history of gastrointestinal ulceration, history of
bronchospasm, asthma, rhinitis, nasal polyps, angioneurotic
oedema or urticaria with intake of NSAID or aspirin therapy,
history of hyper sensibility related to intake of
acetylsalisylsyre, or NSAIDs] were also excluded.
The protocol was approved by ethics committees for hu-
man research at the participating centres and written in-
formed consent was obtained. The authors certify that they
comply with the ethical guidelines for authorship and pub-
lishing of the Journal of Cachexia, Sarcopenia and Muscle.12
Patients were recruited from three centres: St. Olav’s Hospi-
tal, Trondheim University Hospital, Norway; Oslo University
Hospital, Ullevål, Norway; and the Beatson West of Scotland
Cancer Centre, Glasgow, UK.
Randomization
A web-based randomization system developed and adminis-
tered by the Unit of Applied Clinical Research, Department
of Cancer Research and Molecular Medicine, Norwegian
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University of Science and Technology was used.
Randomisations were undertaken in a 1:1 ratio with stratiﬁca-
tion by centre and tumour type. Following baseline assess-
ments, patients were randomised to the treatment arm
(multimodal intervention) or to the control arm. Patients in
the treatment arm had detailed counselling and instruction
from trial research staff, including nurses, physiotherapists,
and dieticians. Patients in the control arm had standard can-
cer care.
The treatment arm consisted of the following:
• Celecoxib 300 mg once daily. Celecoxib was chosen as it is
one of the anti-inﬂammatory drugs most studied in ca-
chexia and it has proved to be beneﬁcial in preserving
weight, performance status, and muscle strength and has
demonstrated to have relatively few side effects.7
• Two 220 mL cartons of ONS (ProSure © Abbott). Each car-
ton contains 1 g EPA, giving a net intake of 2 g/day.
• Nutritional counselling with advice on optimization of nu-
tritional intake that was provided by a dietician and/or
trial nursing staff. A nutritional interview (30 min) was per-
formed at baseline, and then patients were given oral and
written advice on improving energy and protein intake.
Typically, the advice was to increase meal frequency and
use energy dense foods.
• Exercise programme including home-based aerobic and re-
sistance training devised by a physiotherapist. The aerobic
component consisted of 30 min of aerobic exercise of the
patients’ choice two times a week. The resistance exercise
component consisted of six individualised exercises that fol-
low the same schedule, targetingmajormuscle groups in the
upper body and legs, to beperformed three timesweekly for
about 20 min. The exercises consisted of push ups against
the wall, overhead presses, and bicep curls and, for the legs,
squats, lunges, and calf raises with use of weights.
Patients in the treatment arm were contacted a minimum
of once a week (maximum of twice) by telephone to assess
compliance and to encourage adherence to the multimodal
intervention.
The control arm was standard cancer care alone and did
not include regular nutritional or exercise interventions or
NSAIDs. If the treating clinician felt it appropriate, dietician re-
view was carried out. Patients in the control arm were offered
the multimodal intervention after 6 weeks (i.e. after endpoint
assessments) to prevent them mimicking the multimodal in-
tervention and thus contaminating the control arm.
In both arms, patients had regular oncology review. Typi-
cally, this included out-patient appointments prior to chemo-
therapy (pre-chemotherapy assessments) and also hospital
visits (single day) for chemotherapy delivery (most commonly
every 3 weeks). The most common chemotherapy
regimens were Folﬁrinox, Vinorelibine-Carboplatin/Cisplatin,
Gemcitabine mono, and Pemetrexed-Carboplatin/Cisplatin.
All patients had their symptoms managed appropriately,
according to guidelines at each centre.
Procedures
At enrolment, each patient’s demographic details and
disease-related characteristics were recorded. The following
assessments were undertaken at this point (i.e. baseline—
prior to randomisation) and then repeated at trial endpoint
(6 weeks): body weight and body mass index; physical func-
tion [using ActivPAL (physical activity metre worn for 7 days)13
and the 6 min walk test (6MWT)]; muscle mass (using CT as-
sessment of lean muscle mass)14; muscle strength (hand held
dynamometer assessing grip strength); nutritional status
[using abridged Patient Generated Subjective Global Assess-
ment (aPG-SGA)]15; nutritional intake [using a 10 point verbal
scale assessment of nutritional intake (AveS)]16; and fatigue
[assessed using the Fatigue Severity Scale (FSS)].17
Compliance with the EPA enriched ONS was assessed using
patient completed logs. Plasma phospholipid EPA was also
used as a biomarker of compliance with the EPA-enriched
ONS. Compliance with study medication (celecoxib) was
assessed by counting the tablets returned by the patient.
The type and duration of exercise preformed was registered
in a log by the patient. Compliance with the intervention
was assessed at <50%, 50–80%, and >80% of full compliance
within each component of the intervention.
Hospitalizations and adverse events were recorded in ac-
cordance with Good Clinical Practice standards. Adverse
events were graded according to Common Terminology
Criteria for Adverse Events (CTCAE, v3.0).
Routine biochemistry/haematology analyses (albumin,
C-reactive protein, Leucocytes, and creatinine) were per-
formed at baseline and endpoint.
Endpoints
The primary endpoint was feasibility. This was assessed by re-
cruitment and retention (number of patients screened and/or
consented), compliance with the intervention (based on use
of celecoxib, nutritional supplements, and exercise per-
formed), and contamination of the control arm (number of
patients who tried to mimic all or part of the intervention).
Feasibility of recruitment and retention was assessed by
proportion of patients screened vs. those consented and at-
trition rates. In cancer trials, the percentage of patients re-
cruited vs. those screened varies: we accepted 10%
recruitment18 and an attrition rate of <26%19 as feasible.
Compliance with the multimodal intervention was assessed
according to individual components and thresholds of
<50%, 50–80%, and >80% were used. Compliance of ≥50%
of the speciﬁc intervention in ≥50% of patients was
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considered acceptable. The secondary endpoints were as-
sessment of weight, muscle mass (assessed by CT measure-
ment of muscle mass), physical activity (ActivPAL and
6MWT), hand grip strength, nutritional status (AveS and
aPG-SGA score), and fatigue score. These were assessed at
baseline and after 6 weeks (endpoint). Safety and survival
were also assessed as secondary endpoints.
Muscle mass was assessed using CT scan images per-
formed as part of patient management, which were retrieved
from digital storage in the picture archiving and communica-
tion system. Muscle mass levels at L3 are highly correlated to
total body muscle mass (r2 = 0.86).20 Axial images at the L3
level were selected out and analysed using the ‘Automated
Body Composition Analyzer using Computed tomography im-
age Segmentation’ (ABACS) software.21 Using Hounsﬁeld unit
thresholds of 29 to 150 for skeletal muscle, 50 to 150 for
visceral adipose tissue, and 190 to 30 for subcutaneous
adipose tissues, the program recognized shapes and predict-
able patterns to accurately predict values. The sum of skeletal
cross-sectional muscle areas was normalized for stature (m2)
and reported as lumbar skeletal muscle index (cm2m-2).
The primary endpoints were chosen to assess the feasibil-
ity of a delivering a multimodal intervention for cancer ca-
chexia. The secondary endpoints were regarded as
exploratory to inform future trial design, should the primary
endpoints be positive and future trials be deemed
worthwhile.
It was anticipated that most patients entering the trial
would have non-small cell lung cancer. Independent of the
treatment given, the majority of these patients have 2 cycles
of chemotherapy over a total of 6 weeks. The endpoint after
6 weeks was chosen to reﬂect the standard chemotherapy
treatment regimens in the UK and Norway and enabled the
trial to use existing radiological data (CT scans) and assess-
ments to coincide with hospital visits. Further, the trial dura-
tion of 6 weeks was chosen in consideration of selective
attrition that occurs in this advanced cancer population.
Baseline assessment was before randomization and prior to
the start of chemotherapy.
Statistical analysis
An intention to treat approach was used for the primary end-
points. A per protocol approach was used for secondary end-
points. A sample size of approximately 40 patients, 20 for
each arm, was chosen based on an estimation of providing
sufﬁcient information to inform the primary endpoints; feasi-
bility of recruitment and compliance.
In this phase II study, the primary endpoints were mainly
regarded as descriptive, and unless otherwise stated, pre-
sented as medians and inter-quartile ranges or percentages,
as appropriate. For secondary endpoints, to explore the po-
tential that there might be differences between the two
arms, parametric (2 sample t-tests) and non-parametric tests
(Mann–Whitney) were done. Survival analysis was performed
using Kaplan–Meier methods with log-rank test applied. EPA
is expressed as % of total fatty acids quantiﬁed in plasma at
baseline and week 6. Because of the small sample size and
multiplicity of testing, P-values should be interpreted with
caution.
Results
Primary endpoints
From November 2011 to April 2014, 399 patients were
screened resulting in 46 patients being included (Figure 1—
Trial Proﬁle). Recruitment rate (screened vs. consented) was
11.5% (46/399), and this is in keeping with other trials in this
patient population.22 The main reasons for patients not being
eligible were as follows: contraindications to celecoxib, prior
cardiovascular disease/gastric inﬂammatory disease (19%)
or taking an anti-inﬂammatory medication (7%); too frail to
receive chemotherapy (12.5%) and over 80 years of age
(13.0%). The attrition rate of those recruited was 10.9%
(5/46): 8.0% (2/25) in the treatment arm and 14.3% (3/21)
in the control arm.
The analysis was based on the 25 and 21 patients ran-
domly assigned to the treatment and control arms respec-
tively. The baseline characteristics are shown in Table 1.
Groups were well matched with respect to baseline Karnofsky
performance score, cancer type, and prior weight loss.
Patients randomized to the treatment arm were, however,
slightly older, had more advanced stage lung cancer, greater
prior tumour treatment and higher plasma levels of
C-reactive protein.
Compliance with the multimodal intervention is shown in
Table 2. Compliance (deemed as >50% of individual compo-
nents in 50% of patients) was 76% (19/25) for the celecoxib,
60% (15/25) for the exercise components and 48% (12/25)
for the ONS. Therefore, acceptable compliance was achieved
in all but the ONS. Three patients had>80% compliance to all
components of the intervention. In terms of combinations,
eight (38%) patients did >80% of the aerobic and resistance
components. Nine (43%) patients took >80% of the ONS
and celecoxib components and nine (43%) patients took/did
>80% of the resistance and celecoxib components. Two
patients reported reduced compliance with all three compo-
nents during hospitalisations. Some patients reported low
compliance with the exercise component because of fatigue
or not having the time to perform the intervention. Other
reported doing some exercise, but not enough to be compli-
ant. On the basis of the patient logs, patients tended either
to take the ONS as prescribed or not take them at all with
the main reason for not taking ONS was that they did not
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ﬁnd it palatable. At baseline, plasma EPA levels were similar:
1.5% (0.34–4.5%) in the treatment arm (n = 22) and 1.0%
(0.65–2.2%) in the control arm (n = 18) (P = 0.21). At week
6, the plasma EPA level increased to 3% (0.56–8.57%) in the
treatment arm vs. 1.5% (0.63–3.76%) in the control arm
(P = 0.001).
Contamination in the control arm
Only one patient allocated to the control arm tried to mimic
the intervention by taking anti-inﬂammatory medication, nu-
tritional supplements, and exercising. A further three pa-
tients took anti-inﬂammatory medication on their own
initiative; thus, a total of 4/21(20%, CI 6%–48%) patients in
the control arm took an NSAID. There was no evidence of
patients in the control arm taking EPA based on analysis of
EPA levels in blood. There was no evidence of increased
nutritional status (based on both AveS and aPG-SGA scores)
and no evidence of increased physical activity (based on
ActivPAL recordings) in the control arm. No patients in the
control arm were referred to a dietician.
Based on assessments of recruitment, retention, compli-
ance (except for ONS), and contamination, the trial was
feasible.
Secondary endpoints
Weight, muscle mass, physical activity (ActivPAL and 6MWT),
grip strength, nutritional status (aPG-SGA and AveS scores),
and fatigue score per trial arm are shown in Table 3.
Patients in the treatment arm had a mean (SD) increase in
body weight by 0.91 kg (2.47) whereas those in control arm
Figure 1 Trial proﬁle.
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lost 2.12 kg (2.50). Figure 2A shows percentage change in
weight per trial arm. Patients in the treatment arm had amean
(SD) weight increase of 1.29% (3.42) whilst those in the control
arm lost weight, mean (SD) 3.19 (3.67); P < 0.001.
In terms of muscle mass, patients in the both arms lost
muscle. Assessment of muscle mass (using CT derived
measures) between the trial arms is shown in Figure 2B,
and there was no statistical difference between the groups.
There were no notable differences in physical activity
(ActivPAL and 6MWT), grip strength, PG-SGA, and AveS per
trial arm. C-reactive protein was also assessed at follow up
and there was no difference between groups, P = 0.94.
Table 1 Baseline patient demographics and clinical characteristics by trial arm
Characteristic
Treatment arm (n = 25) Control arm (n = 21)
n % Median IQR n % Median IQR
Age (years) 63.0 54.5–68.0 59.0 52.5–67.0
Male gender 15 60 11 52.4
Ethnicity
Caucasian 24 96 21 100
Other 1 4.0 0 0
Primary tumour
NSCLC III 2 8 3 14.3
IV 13 52 8 38.1
Pancreatic III 6 24 5 23.8
IV 4 16 5 23.8
Site of metastases
Bone 4 16 4 19
Liver 2 8 4 19
Lung 4 16 3 14
Lymph node 12 48 8 38
Brain 1 4 0 0
Other 4 16 1 5
Prior treatment
Surgery 4 16 2 9.5
Chemotherapy 4 16 1 4.8
Radiotherapy 4 16 3 14.3
Biochemical parameters
C-reactive protein (mg/L) 12.0 5.0–43.0 6.5 0.3–29.2
Albumin (g/L) 38.5 34.3–42.5 38.0 35.0–43.0
Leucocytes (109/L) 9.0 6.5–11.0 8.0 5.5–9.5
Creatinine (μmol/L) 64.5 55.3–72.8 59.0 55.5–64.5
Assessments
KPS 90.0 80.0–100.0 90.0 80.0–90.0
BMI 24.2 21.4–27.0 24.0 21.9–25.3
Weight loss (%)a 5.7 0.6–13.3 5.4 1.6–11.7
aIn the previous 6 months
BMI, body mass index; IQR, interquartile range; KPS, Karnofsky performance status; NSCLC, non-small cell lung cancer.
Table 2 Compliance levels per intervention component (n = 25)
Intervention component
<50% >50% >80%
n % n % n %
Celecoxib 6 24 2 8 17 68
ONS 13 52 2 8 10 40
Resistance 10 40 3 12 12 48
Aerobic 10 40 3 12 12 48
Aerobic Resistance 14 56 3 12 8 32
Aerobic Resistance ONS 15 60 2 8 4 16
Aerobic Resistance Celecoxib 17 68 2 8 6 24
Aerobic ONS 15 60 1 4 5 20
Aerobic ONS Celecoxib 15 60 1 4 5 20
Resistance ONS 18 72 2 8 5 20
Resistance Celecoxib 14 56 2 8 9 36
Resistance ONS Celecoxib 18 72 2 8 5 20
ONS Celecoxib 15 60 1 4 9 36
Aerobic Resistance ONS Celecoxib 22 88 0 0 3 12
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The median (SD) survival in the treatment arm was 10 (7)
months and in the control arm was 8 (10) months, P = 0.57.
The most common grade 1 and 2 adverse events were nau-
sea, pain, anorexia, constipation, dysgeusia, and dyspnoea
in both trial arms. The most common grade 3 events
(Table 4) were neutropenia and pain. There were in total
101 grade 1 and 2 events in the control arm and 113 grade
1 and 2 events in the treatment arm. None of the reported
events (any grade) were related to cardiac disorders, ulcer,
or renal function or reported related to the study drug. There
were eight Serious Adverse Events in the control arm and 13
in the treatment arm, but none were related to the multi-
modal intervention.
Discussion
This randomized trial integrating nutrition, anti-inﬂammatory
treatment, and exercise to target cancer cachexia
demonstrates that it is feasible to administer a multimodal in-
tervention for cancer cachexia in patients with lung or pan-
creatic cancer, alongside standard anti-cancer cytotoxic
chemotherapy, with the exception of ONS where compliance
was below the minimum expected. The multimodal interven-
tion was safe, and the majority of patients completed the
trial. There was limited evidence of contamination in the con-
trol arm (including plasma EPA measurement, AveS, and aPG-
SGA score) again supporting the feasibility of the trial design.
We also observed that the intervention resulted in a stabiliza-
tion of body weight whilst those patients who did not receive
the intervention, lost weight. However, this ﬁnding must be
interpreted with caution as the trial was not powered to ex-
amine this.
The importance of cachexia as research priority has long
been advocated and this is evidenced by the numerous con-
sensus statements and reviews. In particular, multimodal tri-
als have been recommended; however, the majority of
cachexia trials have used single agents in isolation, or have
lacked a comparator arm.23,24 Where multimodal trials have
Table 3 Weight, muscle mass, physical activity (ActivPAL and 6MWT), grip strength, aPG-SGA score, AveS score, and fatigue score per trial arm.
Treatment arm Control arm
PaMean (SD) Mean (SD)
Weight (kg) n = 23 n = 21
Baseline 70.18(13.03) 66.63 (10.46)
6 weeks 70.82 (14.07) 64.93 (9.88)
Difference 0.91 (2.47) 2.12 (2.50)
% difference 1.29 (3.41) 3.19 (3.67) <0.001
Muscle Mass (CT) cm2 n = 23 n = 20
Baseline 133.79 (25.24) 129.91 (29.61)
6 weeks 130.96 (26.82) 123.07 (31.78)
Difference 2.82 (9.41) 4.97 (7.80)
% difference 0.02 (0.071) 0.042 (0.062) 0.030b
ActivPAL Steps (no of steps) n = 11 n = 11
Baseline 5407 (3485) 3651 (2609)
6 weeks 4872 (2523) 4632 (3171)
Difference 536 (2296) 981 (1694) 0.50
Six minute walk test (meters) n = 19 n = 21
Baseline 474.3 (79.1) 470.2 (87.2)
6 weeks 474.4 (103.3) 490.5 (101.1)
Difference 0.14 (65.2) 20.3 (53.9) 0.32
GripStrength (kg) n = 21 n = 17
Baseline 35.7 (11.5) 32.3 (12.5)
6 weeks 35.3(9.9) 31.5(12.4)
Difference 0.43 (7.24) 0.71 (5.0) 0.69
PG-SGA score (0–36) n = 20 n = 17
Baseline 8.64 (6.34) 10.12 (6.27)
6 weeks 7.70 (7.85) 10.24 (5.52)
Difference 0.80 (5.29) 0.12 (6.67) 0.65
AveS score (0–10) n = 21 n = 16
Baseline 7.74 (2.2) 7.00 (2.42)
6 weeks 7.74 (2.34) 7.06 (1.84)
Difference 0.00 (1.65) 0.06 (1.77) 0.91
Fatigue score (0–10) n = 22 n = 15
Baseline 3.15 (1.84) 3.51 (1.54)
6 weeks 3.85 (1.85) 3.73 (1.94))
Difference 0.69 (1.14) 0.22 (1.77) 0.33
For weight and muscle mass, the P value is based on the percentage change. For the other parameters, the P value is based on raw change.
aPG-SGA, abridged Patient Generated Subjective Global Assessment; AveS, 10 point verbal scale assessment of nutritional intake
a2-sample t-test.
bMann–Whitney.
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been done,25–27 these have examined two or more compo-
nents, and whilst some ﬁndings have been encouraging, to
date, there have been no randomised trials integrating all
the components we consider to be appropriate and this has
resulted in a failure to advance cachexia treatment.28 Our
ﬁndings suggest that multimodal cachexia intervention is safe
and feasible and support further examination of this ap-
proach to fully assess effects on weight and lean body mass
in larger trials.
There are several reasons why cachexia research has been
challenging, and the present study has sought to address
Figure 2 (A) Change in body weight (%) from baseline to endpoint per trial arm. Patients in the treatment arm had mean (SD) increase in weight of
1.29% (3.41) whilst those in the control arm lost 3.19% (3.67). (B) Assessment of muscle mass per trial arm. Patients in the treatment arm had a mean
(SD) loss of muscle mass of 0.02% (0.071) vs. those in the control arm who had a mean (SD) loss of 0.042% (0.062).
Table 4 Adverse events
Treatment arm
(n = 25)
Control arm
(n = 21)
Non-related adverse event
(CTCAE 3.0) Grade 3 Grade 3
Pain 2 2
Neutropenia 2 2
Infection 2 0
GI stricture: intrahepatic duct 0 1
Rectal bleeding 1 0
Total single events 7 5
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these. Deﬁning endpoints in cachexia research has been the
subject of much debate, and at present, there is no consen-
sus on what the optimal endpoint should be. The US Food
and Drug Administration and the European Medicines Agency
suggest that lean body mass gain and improved muscle
strength/power should be used as co-primary endpoints for
the treatment of cancer cachexia. However, this differs from
agreed endpoints in rehabilitation studies for other chronic
wasting conditions [e.g. chronic obstructive pulmonary dis-
ease (COPD)] where patient-centred outcomes such as phys-
ical activity level are used.29
We observed a positive effect on weight in the present
trial; this is encouraging as cachexia-related weight loss is a
key component of cachexia. Body weight is easily measured
in the clinic and it is important to have end-points that can
be implemented in clinical practice. From a patient perspec-
tive, weight loss is associated with psychosocial distress30,31
whilstdeteriorating physical function (e.g. performance status)
is associated with reduced quality of life.32,33 Based on our
observations and supported by previous work, we propose
that weight loss and physical function are favourable end-
points in cancer cachexia trials, being meaningful for both
patients and oncologists. Whilst we have demonstrated that
such endpoints are feasible, adoption into practice requires
ratiﬁcation.
One of the challenges in delivering complex interventions
in cancer patients has been compliance and the present study
provides valuable information on this. As expected, compli-
ance with the anti-inﬂammatory medication was the highest
of all the interventions. With the exercise component and
the nutritional supplements, patients either had very high
compliance or were not compliant, and this is expected in a
real-life clinical setting. It must be anticipated that in a trial
consisting of multiple interventions, compliance with each in-
dividual component will be reduced compared with compli-
ance in a trial consisting of a single intervention. This was
the case in the present trial, and the experience gained will
help reﬁne the multimodal intervention in any future studies.
To illustrate, in patient in whom compliance in the ONS was
low, it may be that ONS that are not enriched with EPA could
be used, and instead, EPA supplementation given via oral cap-
sule. Previous intervention studies have also demonstrated
that compliance with ONS34 and exercise35 can be challeng-
ing, and there is an obvious risk that the control group may
adopt the intervention. However, contamination in the con-
trol arm was limited in the present study, and this clearly
bodes well for future trial designs adopting this approach.
Patients in general complied well with study assessments,
with the exception of the ActivPAL physical activity metre
that had variable compliance. Using an objective measure
of physical function (ActivPAL), as opposed to subjective
measures such as performance status, places the former in
a favourable light; therefore, its role and measures to opti-
mize compliance will be investigated further in future work.
The present trial has limitations. The open label design is
not optimal, however, beyond blinding those analysing the
CT scans and physical activity data, blinding patients or the
staff involved in delivering the multimodal intervention is
challenging; however, it could be argued that a placebo
anti-inﬂammatory, an inert nutritional supplement, and/or
stretching exercises could be used in the control arm. This un-
blinded design may also impact on the subjective outcomes
employed. The design has the risk of control arm contamina-
tion, but in the present trial this was minimal. The sample
size is considered large enough to inform on feasibility; how-
ever, the multiple comparisons performed in the context of
the small sample size mean that ﬁrm conclusions on the
secondary endpoints cannot be drawn. The observation of
improvements in body weight may in part be explicable due
to water retention caused by the NSAID, (0,5–1.0 kg reported
previously).36 However, the absence of signs of gross clinical
oedema (increasing ankle swelling, ascites, and pleural effu-
sions) provides some supporting favourable evidence that
weight gain was not entirely due to expansion of the extracel-
lular water space. Of note was that plasma C-reactive protein
levels were higher in the treatment arm, and as higher
C-reactive protein concentrations have been related to
adverse survival, this may have counterbalanced any survival
advantages conferred by the intervention.37 Clearly the sam-
ple size was not designed to assess such aspects however this
would be of interest in future studies.
Compliance with exercise was assessed using patient logs.
There are clearly some disadvantages with this approach as
these logs may not be completed accurately. Other measures
to assess compliance could have been employed for instance
constant assessment of physical activity (frequency, duration
and intensity) over time using wearable activity meters em-
bedded in armbands or watches (or ‘new generation’ tech-
nology such as SMART phones). However, the present trial
involved multiple interventions in the context of a new can-
cer diagnosis and treatment plan; therefore, we chose mini-
mize patient burden by keeping the activity assessment
simple. Changes in step count are also worthy of mention.
There may have been compensation in both groups with ref-
erence to physical activity as measured by ActivPAL. To illus-
trate, step count increased in the control arm, but decreased
in the treatment arm. One possible reason is that those in the
treatment arm walked less because they exercised more
whilst those in the control arm walked more, by nature of
the unblended intervention; this means that some control
arm contamination may have been present. However, the
small sample size makes interpretation difﬁcult.
Although we recorded which factors affected compliance,
it would have also been of interest to know how satisﬁed
patients were with the multimodal intervention and/or
any beneﬁts that they got. Clearly, this is fundamental, as
the beneﬁts of any treatment only will be realized if
patients take it.
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Conclusions
This trial is the ﬁrst to demonstrate that patients with ad-
vanced cancer who have a high risk of developing cachexia
are willing and able to participate in a randomized controlled
trial of a complex intervention that includes a deﬁned
exercise programme. The positive effect of the multimodal
cachexia intervention on weight provides grounds for opti-
mism that cachexia need not be an inevitable consequence
of advanced cancer but rather may be attenuated through a
multimodal intervention targeting its genesis. A larger, prag-
matic, multimodal phase III trial assessing the effectiveness
of anti-inﬂammatory treatment (EPA/NSAID), nutrition and
exercise in cancer cachexia is now underway (EudraCT
2013-002282-19). Should this demonstrate that such an inter-
vention can prevent or attenuate cancer cachexia; this would
have considerable implications for clinical cancer care
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